Phase 3 N=164 A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis
Knee Osteoarthritis
Primary: Change From Baseline in WOMAC VA3.1 Pain Subscale Score at Month 6 — -23.6; -14.1 mm — p=0.141
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Knee Bracing for People With Patellofemoral Osteoarthritis
Knee Osteoarthritis
Primary: Change in Pain on the VIsual Analog Scale (VAS) — -.068 change in units on a scale from baseline
Phase 3 N=380 Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis
Osteoarthritis · Osteoarthritis, Knee
Primary: Change Form Baseline in WOMAC A Pain Subscale — -11.14; -11.82 cm — p=<0.025
N/A N=36 Durolane SJ for Treatment of Rhizarthrosis
Rhizarthrosis
Primary: Change From Baseline in Pain Measured by the VAS Scale — -2.00 units on a scale
N/A N=7 Preventing Posttraumatic Osteoarthritis With Physical Activity Promotion
Anterior Cruciate Ligament Injuries · Exercise · Cartilage, Articular
Primary: T1rho Relaxation Times in the Medial Femoral Condyle at Baseline — 53.48 ms
N/A N=3,000 Development of an Osteoarthritis (OA) Care Plan to Improve Process and Quality of OA Treatment Decisions
Osteo Arthritis Knee · Osteoarthritis, Hip
Primary: Differences in Decision Conflict Scale With ASK vs Usual Care — 25.1; 26.0 Score on a scale
N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
N/A N=62 Factors Associated With Radiographic Pathophysiology for Trapeziometacarpal Arthrosis in Patients Not Seeking Care for This Condition
Trapeziometacarpal Arthrosis
Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years
Phase 4 N=16 Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab
Osteoarthritis of the Knee
Primary: Change in Cellular Infiltrates From Day 0 to Day 28 — 2; 0; 2; 4 Participants
N/A N=40 Muscle Property, Alignment and Joint Loading in People With Knee Osteoarthritis
Osteoarthritis, Knee
Primary: Change of External Knee Adduction Moment as Assessed by Visual Motion Analysis System — 0.50 Nm/kg
N/A N=25 A Biomarker Stress Test for Detection of Early Osteoarthritis
Osteoarthritis
Primary: Change at 6 Months From Baseline in First Peak Knee Adduction Moment (KAM): (6 Month Value - Baseline) — -0.19 %Bw*Ht
N/A N=23 Jointstrong Intervention for Juvenile Arthritis
Juvenile Arthritis
Primary: Pain — 4.3; 5.7 units on a scale
Phase 1 N=12 Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee
Osteoarthritis, Knee
Primary: Summary of Adverse Events — 2; 2; 3; 2 Adverse events
Phase 2 N=102 Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
Osteoarthritis, Knee
Primary: Change From Baseline in the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Score at 1 Year — 23.3; 9.9 scores on a scale — p=<0.01
N/A N=101 Role of Bone in Knee Osteoarthritis (OA)
Osteoarthritis, Knee
Primary: Number of Participants With Viable Specimens for Genetic Analysis — 14 participants
Phase 2 N=41 A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale
Osteoarthritis, Knee
Primary: Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period — -12.6; -13.6; -11.7; -2.3 Scores on a scale
Phase 2 N=260 Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis
Osteoarthritis of the Knee
Primary: Pain When Walking On A Flat Surface — 0; 1; 8; 4 Participants
Phase 2 N=74 Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
Osteoarthritis, Knee
Primary: Number of Participants Experiencing One or More Treatment-Emergent Adverse Event — 28; 33 Participants — p=>0.9
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
N/A N=58 Mobility Optimization Through Velocity Exercise
Knee Osteoarthritis
Primary: Change in Basic Lower Limb Function (Late Life Function Index) Late Life Function and Disability Instrument — 3.3; -1.0; 3.1; 0.8 units on a scale
N/A N=9 Nutramax Joint Health Formulation Biochemical Response Study
Osteoarthritis, Knee
Primary: Serum Biomarkers — 130; 114; 109; 63 pg/ml
Phase 2 N=100 RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints
Hand Osteoarthritis
Primary: Total Ghent University Scoring System (GUSS) of Target Joints at Week 24 — 162.2; 153.3 units on a scale — p=0.024
N/A N=71 Molecular Pathways Involved in Knee Pain
Knee Osteoarthritis · Knee Pain Chronic
Primary: Pain Sensitivity: Pressure Pain Detection Threshold (PPT) — 252.58; 266.17 kPa
N/A N=41 Hip Osteoarthritis: Effects of Exercise Programs on Pain and Disability
Hip Osteoarthritis
Primary: Change in 6-minute Walk Test — 22; 49 meters
N/A N=23 In Vivo Three-Dimensional Determination of Osteoarthritis Brace Effectiveness
Osteoarthritis, Knee
Primary: Medial Condylar Separation With Brace — 0.60 mm
N/A N=31 Thumb Osteoarthritis: A Cross-Sectional Study of Mechanisms
Carpometacarpal Osteoarthritis
Primary: Australian Canadian OA Hand Index (AUSCAN) — 3.3; 1.3; 2.0; 1.6 score on a scale
N/A N=15 Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee
Osteochondritis Dissecans
Primary: Greater Cartilage Healing Measured by Glycosaminoglycan Content on dGEMRIC MRI
N/A N=25,871 Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain
Autoimmune Diseases · Systemic Inflammatory Process · Knee Pain Chronic
Primary: Serum Levels of Biomarkers of Systemic Inflammation: Interleukin-6 (IL-6) — 1.71; 1.68; 1.69; 1.70 pg/ml — p=0.02
N/A N=32 An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study
Carpometacarpal Osteoarthritis
Primary: The Disabilities of the Arm, Shoulder and Hand Outcome Measure — 12.6 units on a scale
Phase 3 N=163 Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand
Osteoarthrosis
Primary: Change in Global Spontaneous Pain Intensity of Target Hand — -20; -11.3 mm — p=0.016